A Study of ALG-000184 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single and Multiple Doses in Healthy Volunteers and CHB Subjects
← catalyst calendarSponsored by Aligos Therapeutics (industry) · ALGS — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
165actual
Sites
10
Countries
Australia, China, Hong Kong +3
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2020-10-22 | actual | When the study began enrolling |
| Primary completion | 2025-06-16 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-06-16 | actual | The whole study's end, after follow-up |
| First posted | 2020-09-02 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-11-21 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Chronic Hepatitis B
Interventions
- Drug: ALG-000184
- Drug: Placebo
- Drug: Entecavir
Primary outcomes
what the primary-completion date above is the date OFIncidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
measured up to 8 days for Part 1
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
measured up to 21 days for Part 2
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
measured up to 112 days for Part 3
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
measured Up to 756 days for parts 4 & 5
Publications
- PMID 41554267 — linked by the registry
- PMID 41268712 — linked by the registry
- PMID 34280012 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · ALGS's whole pipeline · Catalyst calendar · Every registered study · What changed